During the past decade, enormous progress has been made in research for biomarkers in Alzheimer's disease. Biomarkers have now been incorporated in the currently proposed research criteria for Alzheimer's disease1,2 to increase the confidence that a cognitive impairment is due to Alzheimer's disease or to identify the disease in its preclinical stages before onset of dementia. These criteria include biomarkers of β amyloidosis (A) and neurodegeneration (N) and classification of each biomarker as normal (−) or abnormal (+), resulting in four biomarker states: A−N−, A+N−, A−N+, and A+N+.
Article Info
No comments:
Post a Comment